Literature DB >> 10502285

Retinoic acid and 1,25-dihydroxyvitamin D3 inhibit tenascin-C expression in rat glioma C6 cells.

M Alvarez-Dolado1, J M González-Sancho, C Navarro-Yubero, L F García-Fernández, A Muñoz.   

Abstract

Tenascin-C (Tn-C) is an extracellular matrix protein with growth-, invasive-, and angiogenesis-promoting activities. Tn-C is upregulated during wound healing, tumorigenesis, and other pathological conditions. Highly malignant gliomas with poor prognosis exhibit high levels of Tn-C expression. Here we demonstrate that Tn-C RNA expression in glioma C6 cells is inhibited in a dose-dependent manner by retinoic acid (RA) and 1,25-dihydroxyvitamin D3 (1,25-D3). No additive or synergistic effects were found. Inhibition is maximum 24 hr after RA or 1,25-D3 treatment, prior to a delayed cytotoxic effect starting at day 4-5 of treatment, and correlates with a reduction in the synthesis of Tn-C protein. Tn-C expression is also inhibited, but to a lesser extent by prostaglandin D2 (PGD2). Furthermore, both RA and 1,25-D3, but not PGD2 abolish the induction of Tn-C by the tumor promoter 12-O-tetradecanoyl phorbol 13-acetate. The inhibition of Tn-C expression might be relevant for the anti-cancer activity of RA and 1,25-D3. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502285     DOI: 10.1002/(sici)1097-4547(19991015)58:2<293::aid-jnr9>3.0.co;2-h

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  6 in total

Review 1.  From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM.

Authors:  Ilhan Elmaci; Aysel Ozpinar; Alp Ozpinar; Jennifer L Perez; Meric A Altinoz
Journal:  Metab Brain Dis       Date:  2019-04-01       Impact factor: 3.584

Review 2.  Vitamin D3 from Ultraviolet-B Exposure or Oral Intake in Relation to Cancer Incidence and Mortality.

Authors:  William B Grant; Meis Moukayed
Journal:  Curr Nutr Rep       Date:  2019-09

3.  13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme.

Authors:  Siew-Ju See; Victor A Levin; W-K Alfred Yung; Kenneth R Hess; Morris D Groves
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

4.  ATRA-inhibited proliferation in glioma cells is associated with subcellular redistribution of beta-catenin via up-regulation of Axin.

Authors:  Jianrong Lu; Feng Zhang; Daqing Zhao; Liu Hong; Jie Min; Liying Zhang; Fanfan Li; Yan Yan; Hang Li; Yu Ma; Qing Li
Journal:  J Neurooncol       Date:  2008-01-23       Impact factor: 4.130

Review 5.  Anti-tumor effects of vitamin D in glioblastoma: mechanism and therapeutic implications.

Authors:  Carmen Sze-Ching Lo; Karrie Mei-Yee Kiang; Gilberto Ka-Kit Leung
Journal:  Lab Invest       Date:  2021-09-09       Impact factor: 5.662

6.  Neural progenitor fate decision defects, cortical hypoplasia and behavioral impairment in Celsr1-deficient mice.

Authors:  C Boucherie; C Boutin; Y Jossin; O Schakman; A M Goffinet; L Ris; P Gailly; F Tissir
Journal:  Mol Psychiatry       Date:  2017-12-19       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.